{"id":45594,"date":"2025-11-03T14:38:21","date_gmt":"2025-11-03T06:38:21","guid":{"rendered":"https:\/\/flcube.com\/?p=45594"},"modified":"2025-11-03T14:38:22","modified_gmt":"2025-11-03T06:38:22","slug":"betta-pharma-secures-exclusive-greater%e2%80%91china-rights-to-gensciences-long%e2%80%91acting-factor-viii-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45594","title":{"rendered":"Betta Pharma Secures Exclusive Greater\u2011China Rights to Gensciences\u2019 Long\u2011Acting Factor\u202fVIII Therapy"},"content":{"rendered":"\n<p><strong>Betta Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/300558:SHE\">SHE: 300558<\/a>) announced today the signing of a <strong>Strategic Cooperation Framework Agreement<\/strong> and a <strong>Commercial Cooperation Agreement<\/strong> with <strong>Gensciences<\/strong>. The partnership gives Betta Pharma full responsibility for the <strong>research, development, clinical\u2011trial execution, manufacturing, registration, and sales promotion<\/strong> of Gensciences\u2019 pipeline in China, and grants it <strong>exclusive general distribution rights<\/strong> for the recombinant coagulation product <strong>FRSW117 (Recombinant Human Coagulation Factor\u202fVIII\u2011Fc Fusion Protein for Injection)<\/strong> across the Greater\u2011China region (Mainland China, Hong\u202fKong SAR, Macao SAR, and Taiwan).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-cooperation-highlights\">Strategic Cooperation Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Area of Collaboration<\/th><th>Betta Pharma\u2019s Role<\/th><\/tr><\/thead><tbody><tr><td><strong>R&amp;D &amp; Clinical Trials<\/strong><\/td><td>Provide local scientific expertise, site management, and regulatory liaison for ongoing and future studies.<\/td><\/tr><tr><td><strong>Manufacturing &amp; Production<\/strong><\/td><td>Support technology transfer, scale\u2011up, and quality\u2011control activities at Betta\u2019s GMP\u2011certified facilities.<\/td><\/tr><tr><td><strong>Regulatory Registration<\/strong><\/td><td>Lead submission of the New Drug Application (NDA) to the National Medical Products Administration (NMPA).<\/td><\/tr><tr><td><strong>Sales &amp; Marketing<\/strong><\/td><td>Design and execute market\u2011entry strategies, physician education, and patient\u2011support programs.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-agreement-details\">Commercial Agreement Details<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Product:<\/strong> FRSW117 \u2013 Recombinant Human Coagulation Factor\u202fVIII\u2011Fc Fusion Protein for Injection<\/li>\n\n\n\n<li><strong>Therapeutic Class:<\/strong> Category\u202f1 therapeutic biologic (long\u2011acting recombinant Factor\u202fVIII)<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Routine prophylaxis, on\u2011demand treatment, and peri\u2011operative bleeding management in patients with <strong>hemophilia\u202fA<\/strong>.<\/li>\n\n\n\n<li><strong>Dosing Frequency:<\/strong> Once\u2011weekly for prophylaxis (significantly reduces treatment burden).<\/li>\n\n\n\n<li><strong>Market Status:<\/strong> <strong>First domestically produced long\u2011acting recombinant Factor\u202fVIII<\/strong> to receive Chinese regulatory approval (pending).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need:<\/strong> China currently has <strong>no approved domestic long\u2011acting recombinant Factor\u202fVIII<\/strong> products, creating a large therapeutic gap for the estimated <strong>>30,000 hemophilia\u202fA<\/strong> patients.<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Bloomberg estimates the Chinese hemophilia market could exceed <strong>USD\u202f1.2\u202fbillion<\/strong> by 2028; a weekly\u2011dosed product like FRSW117 is positioned to capture a sizable share.<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> Betta\u2019s established <strong>distribution network<\/strong> and <strong>clinical\u2011trial infrastructure<\/strong> give the product a faster go\u2011to\u2011market timeline than foreign competitors.<\/li>\n\n\n\n<li><strong>Regulatory Timeline:<\/strong> Phase\u202f3 trial data have been submitted; Betta expects <strong>NMPA filing Q2\u202f2026<\/strong> with a potential <strong>approval window in late\u20112026<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-about-betta-pharmaceuticals\">About Betta Pharmaceuticals<\/h2>\n\n\n\n<p>Betta Pharma is a <strong>China\u2011focused biopharmaceutical company<\/strong> specializing in the development, manufacturing, and commercialization of innovative biologics. The firm leverages a <strong>state\u2011of\u2011the\u2011art GMP platform<\/strong> and a <strong>nationwide sales force<\/strong> to bring high\u2011value therapies to Chinese patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-about-gensciences\">About Gensciences<\/h2>\n\n\n\n<p>Gensciences is a <strong>global biotech firm<\/strong> with a pipeline centered on <strong>recombinant protein therapeutics<\/strong> for rare bleeding disorders and other specialty indications. Its flagship product, <strong>FRSW117<\/strong>, is a <strong>Fc\u2011fusion engineered Factor\u202fVIII<\/strong> designed for extended half\u2011life and reduced dosing frequency.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements regarding the strategic partnership, product development, regulatory approvals, and market potential. Actual results may differ materially due to risks including regulatory outcomes, clinical trial results, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0e\u665f\u65af\u751f\u7269\u8fbe\u6210\u6218\u7565\u5408\u4f5c\u66a8\u7b7e\u7f72\u300a\u5546\u4e1a\u5408\u4f5c\u534f\u8bae\u300b\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0e\u665f\u65af\u751f\u7269\u8fbe\u6210\u6218\u7565\u5408\u4f5c\u66a8\u7b7e\u7f72\u300a\u5546\u4e1a\u5408\u4f5c\u534f\u8bae\u300b\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-4f550cab-9be8-4984-a1f2-a635becee6ec\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0e\u665f\u65af\u751f\u7269\u8fbe\u6210\u6218\u7565\u5408\u4f5c\u66a8\u7b7e\u7f72\u300a\u5546\u4e1a\u5408\u4f5c\u534f\u8bae\u300b\u7684\u516c\u544a.pdf\">\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0e\u665f\u65af\u751f\u7269\u8fbe\u6210\u6218\u7565\u5408\u4f5c\u66a8\u7b7e\u7f72\u300a\u5546\u4e1a\u5408\u4f5c\u534f\u8bae\u300b\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u4e0e\u665f\u65af\u751f\u7269\u8fbe\u6210\u6218\u7565\u5408\u4f5c\u66a8\u7b7e\u7f72\u300a\u5546\u4e1a\u5408\u4f5c\u534f\u8bae\u300b\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4f550cab-9be8-4984-a1f2-a635becee6ec\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced today the signing of a Strategic Cooperation Framework&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45597,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[231,30,4422,1030],"class_list":["post-45594","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-betta-pharmaceuticals","tag-biotech","tag-gensciences","tag-she-300558"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Betta Pharma Secures Exclusive Greater\u2011China Rights to Gensciences\u2019 Long\u2011Acting Factor\u202fVIII Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced today the signing of a Strategic Cooperation Framework Agreement and a Commercial Cooperation Agreement with Gensciences. The partnership gives Betta Pharma full responsibility for the research, development, clinical\u2011trial execution, manufacturing, registration, and sales promotion of Gensciences\u2019 pipeline in China, and grants it exclusive general distribution rights for the recombinant coagulation product FRSW117 (Recombinant Human Coagulation Factor\u202fVIII\u2011Fc Fusion Protein for Injection) across the Greater\u2011China region (Mainland China, Hong\u202fKong SAR, Macao SAR, and Taiwan).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45594\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Betta Pharma Secures Exclusive Greater\u2011China Rights to Gensciences\u2019 Long\u2011Acting Factor\u202fVIII Therapy\" \/>\n<meta property=\"og:description\" content=\"Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced today the signing of a Strategic Cooperation Framework Agreement and a Commercial Cooperation Agreement with Gensciences. The partnership gives Betta Pharma full responsibility for the research, development, clinical\u2011trial execution, manufacturing, registration, and sales promotion of Gensciences\u2019 pipeline in China, and grants it exclusive general distribution rights for the recombinant coagulation product FRSW117 (Recombinant Human Coagulation Factor\u202fVIII\u2011Fc Fusion Protein for Injection) across the Greater\u2011China region (Mainland China, Hong\u202fKong SAR, Macao SAR, and Taiwan).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45594\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T06:38:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-03T06:38:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0309.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45594#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45594\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Betta Pharma Secures Exclusive Greater\u2011China Rights to Gensciences\u2019 Long\u2011Acting Factor\u202fVIII Therapy\",\"datePublished\":\"2025-11-03T06:38:21+00:00\",\"dateModified\":\"2025-11-03T06:38:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45594\"},\"wordCount\":472,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45594#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0309.webp\",\"keywords\":[\"Betta Pharmaceuticals\",\"Biotech\",\"Gensciences\",\"SHE: 300558\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45594#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45594\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45594\",\"name\":\"Betta Pharma Secures Exclusive Greater\u2011China Rights to Gensciences\u2019 Long\u2011Acting Factor\u202fVIII Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45594#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45594#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0309.webp\",\"datePublished\":\"2025-11-03T06:38:21+00:00\",\"dateModified\":\"2025-11-03T06:38:22+00:00\",\"description\":\"Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced today the signing of a Strategic Cooperation Framework Agreement and a Commercial Cooperation Agreement with Gensciences. The partnership gives Betta Pharma full responsibility for the research, development, clinical\u2011trial execution, manufacturing, registration, and sales promotion of Gensciences\u2019 pipeline in China, and grants it exclusive general distribution rights for the recombinant coagulation product FRSW117 (Recombinant Human Coagulation Factor\u202fVIII\u2011Fc Fusion Protein for Injection) across the Greater\u2011China region (Mainland China, Hong\u202fKong SAR, Macao SAR, and Taiwan).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45594#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45594\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45594#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0309.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0309.webp\",\"width\":1080,\"height\":608,\"caption\":\"Betta Pharma Secures Exclusive Greater\u2011China Rights to Gensciences\u2019 Long\u2011Acting Factor\u202fVIII Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45594#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Betta Pharma Secures Exclusive Greater\u2011China Rights to Gensciences\u2019 Long\u2011Acting Factor\u202fVIII Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Betta Pharma Secures Exclusive Greater\u2011China Rights to Gensciences\u2019 Long\u2011Acting Factor\u202fVIII Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced today the signing of a Strategic Cooperation Framework Agreement and a Commercial Cooperation Agreement with Gensciences. The partnership gives Betta Pharma full responsibility for the research, development, clinical\u2011trial execution, manufacturing, registration, and sales promotion of Gensciences\u2019 pipeline in China, and grants it exclusive general distribution rights for the recombinant coagulation product FRSW117 (Recombinant Human Coagulation Factor\u202fVIII\u2011Fc Fusion Protein for Injection) across the Greater\u2011China region (Mainland China, Hong\u202fKong SAR, Macao SAR, and Taiwan).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45594","og_locale":"en_US","og_type":"article","og_title":"Betta Pharma Secures Exclusive Greater\u2011China Rights to Gensciences\u2019 Long\u2011Acting Factor\u202fVIII Therapy","og_description":"Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced today the signing of a Strategic Cooperation Framework Agreement and a Commercial Cooperation Agreement with Gensciences. The partnership gives Betta Pharma full responsibility for the research, development, clinical\u2011trial execution, manufacturing, registration, and sales promotion of Gensciences\u2019 pipeline in China, and grants it exclusive general distribution rights for the recombinant coagulation product FRSW117 (Recombinant Human Coagulation Factor\u202fVIII\u2011Fc Fusion Protein for Injection) across the Greater\u2011China region (Mainland China, Hong\u202fKong SAR, Macao SAR, and Taiwan).","og_url":"https:\/\/flcube.com\/?p=45594","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-03T06:38:21+00:00","article_modified_time":"2025-11-03T06:38:22+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0309.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45594#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45594"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Betta Pharma Secures Exclusive Greater\u2011China Rights to Gensciences\u2019 Long\u2011Acting Factor\u202fVIII Therapy","datePublished":"2025-11-03T06:38:21+00:00","dateModified":"2025-11-03T06:38:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45594"},"wordCount":472,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45594#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0309.webp","keywords":["Betta Pharmaceuticals","Biotech","Gensciences","SHE: 300558"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45594#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45594","url":"https:\/\/flcube.com\/?p=45594","name":"Betta Pharma Secures Exclusive Greater\u2011China Rights to Gensciences\u2019 Long\u2011Acting Factor\u202fVIII Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45594#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45594#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0309.webp","datePublished":"2025-11-03T06:38:21+00:00","dateModified":"2025-11-03T06:38:22+00:00","description":"Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced today the signing of a Strategic Cooperation Framework Agreement and a Commercial Cooperation Agreement with Gensciences. The partnership gives Betta Pharma full responsibility for the research, development, clinical\u2011trial execution, manufacturing, registration, and sales promotion of Gensciences\u2019 pipeline in China, and grants it exclusive general distribution rights for the recombinant coagulation product FRSW117 (Recombinant Human Coagulation Factor\u202fVIII\u2011Fc Fusion Protein for Injection) across the Greater\u2011China region (Mainland China, Hong\u202fKong SAR, Macao SAR, and Taiwan).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45594#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45594"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45594#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0309.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0309.webp","width":1080,"height":608,"caption":"Betta Pharma Secures Exclusive Greater\u2011China Rights to Gensciences\u2019 Long\u2011Acting Factor\u202fVIII Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45594#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Betta Pharma Secures Exclusive Greater\u2011China Rights to Gensciences\u2019 Long\u2011Acting Factor\u202fVIII Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0309.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45594"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45594\/revisions"}],"predecessor-version":[{"id":45599,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45594\/revisions\/45599"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45597"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}